Market Cap | 360.83M | P/E | - | EPS this Y | 7.80% | Ern Qtrly Grth | - |
Income | -96.71M | Forward P/E | -4.17 | EPS next Y | 2.80% | 50D Avg Chg | -8.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 18.00% |
Dividend | N/A | Price/Book | 1.80 | EPS next 5Y | - | 52W High Chg | -47.00% |
Recommedations | 2.20 | Quick Ratio | 17.59 | Shares Outstanding | 50.23M | 52W Low Chg | 282.00% |
Insider Own | 3.47% | ROA | -26.73% | Shares Float | 29.30M | Beta | 1.28 |
Inst Own | 87.64% | ROE | -42.23% | Shares Shorted/Prior | 321.31K/1.09M | Price | 8.71 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 234,361 | Target Price | 18.50 |
Oper. Margin | - | Earnings Date | - | Volume | 104,530 | Change | 1.52% |
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Jan 30 | Sell | 15.29 | 15,000 | 229,350 | 358,657 | 02/02/24 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Jan 30 | Option | 1.04 | 15,000 | 15,600 | 373,657 | 02/02/24 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Jan 22 | Option | 0.94 | 98,016 | 92,135 | 358,657 | 01/23/24 |
Kanesa-thasan Niranjan | Chief Medical Office.. Chief Medical Officer | Jan 04 | Sell | 15.7 | 106,373 | 1,670,056 | 223,980 | 01/05/24 |
Kanesa-thasan Niranjan | Chief Medical Office.. Chief Medical Officer | Jan 04 | Option | 5.7 | 106,373 | 606,326 | 330,353 | 01/05/24 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Jan 02 | Sell | 15.67 | 15,000 | 235,050 | 260,641 | 01/04/24 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Jan 02 | Option | 1.04 | 15,000 | 15,600 | 275,641 | 01/04/24 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Dec 20 | Sell | 15.44 | 152,205 | 2,350,045 | 260,641 | 12/22/23 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Dec 20 | Option | 1.45 | 165,917 | 240,580 | 350,641 | 12/22/23 |
Russo Thomas Joseph | Chief Financial Offi.. Chief Financial Officer | Dec 20 | Sell | 15.46 | 15,183 | 234,729 | 38,037 | 12/22/23 |
Kanesa-thasan Niranjan | Chief Medical Office.. Chief Medical Officer | Dec 20 | Sell | 15.4571 | 11,884 | 183,692 | 223,980 | 12/22/23 |
Cearley Cassia | Chief Business Offic.. Chief Business Officer | Dec 20 | Sell | 15.4571 | 7,934 | 122,637 | 130,694 | 12/22/23 |
Cearley Cassia | Chief Business Offic.. Chief Business Officer | Dec 13 | Sell | 16.0053 | 8,759 | 140,190 | 131,200 | 12/15/23 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Aug 01 | Option | 0.84 | 3,000 | 2,520 | 246,930 | 08/01/23 |
Kanesa-thasan Niranjan | Chief Medical Office.. Chief Medical Officer | Jul 31 | Sell | 8.8615 | 3,323 | 29,447 | 235,864 | 08/01/23 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Jul 31 | Sell | 8.8615 | 11,788 | 104,459 | 243,930 | 08/01/23 |
Russo Thomas Joseph | Chief Financial Offi.. Chief Financial Officer | Jul 31 | Sell | 8.8615 | 3,066 | 27,169 | 45,620 | 08/01/23 |
Cearley Cassia | Chief Business Offic.. Chief Business Officer | Jul 31 | Sell | 8.8615 | 1,888 | 16,731 | 139,959 | 08/01/23 |
Holtzman Douglas | Chief Scientific Off.. Chief Scientific Officer | Jul 03 | Sell | 9.16 | 16,356 | 149,821 | 290,054 | 07/03/23 |
Holtzman Douglas | Chief Scientific Off.. Chief Scientific Officer | Jul 03 | Option | 1.04 | 16,356 | 17,010 | 306,410 | 07/03/23 |
Cearley Cassia | Chief Business Offic.. Chief Business Officer | May 23 | Sell | 10.00 | 10,000 | 100,000 | 141,847 | 05/25/23 |
Holtzman Douglas | Chief Scientific Off.. Chief Scientific Officer | Apr 03 | Sell | 6.32 | 20,443 | 129,200 | 290,054 | 04/05/23 |
Holtzman Douglas | Chief Scientific Off.. Chief Scientific Officer | Apr 03 | Option | 1.04 | 20,443 | 21,261 | 310,497 | 04/05/23 |
Cearley Cassia | Chief Business Offic.. Chief Business Officer | Mar 06 | Sell | 7.7474 | 5,000 | 38,737 | 151,847 | 03/08/23 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Feb 15 | Option | 1.04 | 10,677 | 11,104 | 255,718 | 02/16/23 |
Bekiroglu Elizabeth | General Counsel & Co.. General Counsel & Corp. Sec. | Feb 13 | Sell | 10.6926 | 5,922 | 63,322 | 103,007 | 02/15/23 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Feb 13 | Sell | 10.6926 | 7,506 | 80,259 | 245,041 | 02/15/23 |
Holtzman Douglas | Chief Scientific Off.. Chief Scientific Officer | Feb 13 | Sell | 10.43 | 4,871 | 50,805 | 290,054 | 02/15/23 |
Russo Thomas Joseph | Chief Financial Offi.. Chief Financial Officer | Feb 13 | Sell | 10.6926 | 1,902 | 20,337 | 48,686 | 02/15/23 |
Kanesa-thasan Niranjan | Chief Medical Office.. Chief Medical Officer | Feb 13 | Sell | 10.6926 | 1,794 | 19,183 | 239,187 | 02/15/23 |
Cearley Cassia | Chief Business Offic.. Chief Business Officer | Feb 13 | Sell | 10.6926 | 1,660 | 17,750 | 156,847 | 02/15/23 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Jan 25 | Option | 0.94 | 13,073 | 12,289 | 252,547 | 01/27/23 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Dec 21 | Sell | 8.96 | 66,764 | 598,205 | 225,105 | 12/23/22 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Dec 21 | Option | 0.84 | 14,369 | 12,070 | 239,474 | 12/23/22 |
Holtzman Douglas | Chief Scientific Off.. Chief Scientific Officer | Dec 15 | Sell | 11.1443 | 19,648 | 218,963 | 2,792 | 12/16/22 |
Bekiroglu Elizabeth | General Counsel & Co.. General Counsel & Corp. Sec. | Sep 08 | Sell | 4.8731 | 1,813 | 8,835 | 108,929 | 09/09/22 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Jul 29 | Sell | 6.82 | 11,377 | 77,591 | 291,869 | 08/02/22 |
Russo Thomas Joseph | Chief Financial Offi.. Chief Financial Officer | Jul 29 | Sell | 6.82 | 2,959 | 20,180 | 48,921 | 08/02/22 |
Holtzman Douglas | Chief Scientific Off.. Chief Scientific Officer | Jul 29 | Sell | 6.82 | 10,375 | 70,758 | 293,258 | 08/02/22 |
Richardson Charles E | SVP, Technical Opera.. SVP, Technical Operations | Jul 29 | Sell | 6.82 | 2,218 | 15,127 | 165,168 | 08/02/22 |
Kanesa-thasan Niranjan | Chief Medical Office.. Chief Medical Officer | Jul 29 | Sell | 6.82 | 3,245 | 22,131 | 239,314 | 08/02/22 |
Cearley Cassia | Chief Business Offic.. Chief Business Officer | Jul 29 | Sell | 6.82 | 1,812 | 12,358 | 131,738 | 08/02/22 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Jul 01 | Option | 0.84 | 7,185 | 6,035 | 303,245 | 07/06/22 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Mar 28 | Option | 0.84 | 4,789 | 4,023 | 220,482 | 03/30/22 |
Cearley Cassia | Chief Business Offic.. Chief Business Officer | Mar 07 | Sell | 17.47 | 10,000 | 174,700 | 98,413 | 03/09/22 |
Richardson Charles E | SVP, Technical Opera.. SVP, Technical Operations | Feb 14 | Option | 0.94 | 72,561 | 68,207 | 167,386 | 02/16/22 |
Kanesa-thasan Niranjan | Chief Medical Office.. Chief Medical Officer | Feb 02 | Option | 0.94 | 52,752 | 49,587 | 221,408 | 02/04/22 |
Simpson Adam K. | Chief Executive Offi.. Chief Executive Officer | Jan 26 | Option | 0.94 | 90,693 | 85,251 | 215,693 | 01/28/22 |